Compounds / Other / Melanotan I

Melanotan I

Melanotan I (Afamelanotide — MC1R Selective Agonist)
OtherFDA ApprovedFDA: FDA-APPROVED (Scenesse) for...

Overview

FDA-approved (Scenesse) for erythropoietic protoporphyria (EPP) — rare condition causing extreme photosensitivity. Research: general photoprotection, skin cancer prevention.

Mechanism of Action

Selective MC1R agonist. Stimulates eumelanin production (tanning). Photoprotection. Unlike MT-II, highly selective — minimal MC4R activity. Even pigmentation without UV exposure.

Molecular Profile

Molecular weight
1646.9 Da
CAS number
75921-69-6

Key Research Findings

Selective MC1R; photoprotection; FDA-approved for EPP; even pigmentation; minimal MC4R side effects.

Published Research

NEJM (2015)
Langendonk JG et al. Afamelanotide for erythropoietic protoporphyria
View source

Related Other Compounds

PT-141Melanotan IIPNC-27CystagenDermorphinEPO
Clinical Guidance

Research data is not a treatment plan. If you are considering Melanotan I, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running Melanotan I? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals